Accès ouvert
2026
editorial
OpenAlex
Emma Guilbaud, Edna Cukierman, Igor Astsaturov, Lorenzo Galluzzi
Autophagy promotes tumor progression and immune evasion by numerous mechanisms, representing a promising target for novel (immuno)therapeutic interventions in multiple oncological indications. An expanding literature, however, suggests that safely and effectively targeting autophagy in the clinic remains challenging, especially in populations as …
us
(code pays fourni par la source)
Accès ouvert
2026
review
OpenAlex
Emma Guilbaud, Kevin M. Ryan, Douglas R. Green, Lorenzo Galluzzi
us, gb
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Emma Guilbaud, Ai Sato, Lorenzo Galluzzi.
Abstract Estrogen receptor-positive (ER+) breast cancer (BC) lesions are poorly infiltrated by lymphocytes (immunologically "cold") and are therefore insensitive to immune checkpoint inhibitors (ICIs). Radiation therapy (RT) represents a clinically promising partner for ICIs, as RT converts immunologically "cold" ER+ BC into …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
S Durdević, Emma Guilbaud, Yohan Trichet
Cette étude part du constat que la notion de formes discrètes de psychose a pratiquement disparu des systèmes diagnostiques contemporains des maladies mentales. Face à cette impasse, nous proposons une lecture des contributions lacaniennes sur cette question, à partir de son dernier …
fr
(code pays fourni par la source)
2026
article
OpenAlex
Manuel Beltrán‐Visiedo, Emma Guilbaud, Ruth Soler-Agesta
Accès ouvert
2025
article
OpenAlex
Ainhoa Ruiz-Iglesias, Emma Guilbaud, Lorenzo Galluzzi, Santos Mañes
Type I interferon (IFN) has long been known as a critical component of the molecular machinery that first responds to viral infection in multicellular eukaryotes. More recently, type I IFN signaling has also emerged as a common process in the microenvironment of …
es, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Ruth Soler-Agesta, Manuel Beltrán‐Visiedo, Ai Sato, Takahiro Yamazaki et autres
PT-112 is a novel small molecule exhibiting promising clinical activity in patients with solid tumors. PT-112 kills malignant cells by inhibiting ribosome biogenesis while promoting the emission of immunostimulatory signals. Accordingly, PT-112 is an authentic immunogenic cell death (ICD) inducer and synergizes …
us, es
(code pays fourni par la source)
2025
article
OpenAlex
Emma Guilbaud, Flavie Naulin, Lydia Meziani, Éric Deutsch et autres
us, fr
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Emma Guilbaud, Lorenzo Galluzzi
In a recent study published in Nature Immunology , Shen et al. have proposed that the caspase 3 (CASP3)-dependent cleavage of interleukin 18 (IL18) in malignant cells exposed to apoptotic inducers generates a short IL18 fragment that operates intracellularly to promote the …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Manuel Beltrán‐Visiedo, Ruth Soler-Agesta, Emma Guilbaud, Ai Sato et autres
Abstract In 2023, an estimated 297,790 new cases of invasive breast cancer (BC) have been diagnosed to women in the US, causing an estimated 55,720 deaths, most of which originated from hormone receptor (HR+) BC. In this sense, radiation therapy (RT) has …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Lorenzo Galluzzi, Emma Guilbaud, Abhishek D. Garg
us, be
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Manuel Beltrán Visiedo, Ruth Soler Agesta, Emma Guilbaud, Ai Sato et autres
Background In 2023, an estimated 297,790 new cases of invasive breast cancer (BC) have been diagnosed to women in the US, causing an estimated 55,720 deaths, most of which originated from hormone receptor (HR+) BC. In this sense, radiation therapy (RT) has …
us, es, il
(code pays fourni par la source)